Doctorz Blox TM Evidence Medicine

.Evidence Medicine TM
zBlox.com

facebook f zb

 

  • Acute Coronary Syndrome AHA 2012 Question 1
  • Q 2
  • Q 3

    Aug 22, 2012
    According to the
    2012 ACCF/AHA Focused Update of the Guideline for the Management  of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction  (PDF) (p 651)

    In the PLATO trial “comparing ticagrelor with clopidogrel (on a background of aspirin therapy)  . . . for the prevention of vascular events and death in  . . .  ACS” . . .  “patients enrolled in North America” showed “_________ differences between ticagrelor and clopidogrel with respect to the primary efficacy endpoint ”
    One possible explanation was that “a significantly higher proportion of patients in the United States received a median aspirin dose of  _______ compared with the rest of the world . . . ”

    a) the greatest ; < 300 mg daily
    b) the greatest ; >/=300 mg daily
    c) no statistically significant ; < 300 mg daily
    d) no statistically significant ; >/=300 mg daily

    • Answer
  • Q 4
  • Q 5
  • Q 6
  • Q 7
  • Q 8
  • Q 9
  • Q 10
  • 2012 ACP/ACC Stable Ischemic Heart Disease Quiz

Evidence Medicine (TM) / EvidMed (TM) / DoctorzBlox (TM) (c) 2001- 2013 zBlox.com
wHealthQ launched June 1, 2013
DrugzBlox (TM) launched July 1, 2013
R Q D G C F SQ P EM2 EM1
facebook f zb